Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M17D1 in HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors
NCT06714617Phase 1Terminated
- Sponsor
- SystImmune Inc.
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BL-M17D1 in solid tumor, breast cancer, gastric cancer (GC) and 7 more (3 arms), sponsored by SystImmune Inc. Primary endpoints: Dose-limiting toxicities at 1 year, Serious Adverse Events and Treatment-Emergent Adverse Events at 1 year and 1 more. Started Apr 2025; status: terminated.
02
Drugs
BL-M17D1
03
Conditions
solid tumorbreast cancergastric cancer (GC)gastroesophageal junction cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06714617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714617.